Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress
October 21 2019 - 9:15AM
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader
in gene and cell therapy, today announced the presentations of data
from the Transpher A Study, the Company’s ongoing Phase 1/2
clinical trial evaluating ABO-102 for the treatment of Sanfilippo
syndrome type A (MPS IIIA), and research updates from its library
of novel AIMTM adeno-associated virus (AAV) capsids at the 27th
European Society of Gene and Cell Therapy (ESGCT) Congress, to be
held October 22-25, 2019 in Barcelona, Spain.
The data will be presented as follows:
Safety, Tolerability, Biopotency and Neurocognitive Data of
ABO-102 in Transpher A, an Open-Label, Multicenter, Single-Dose,
Dose-Escalation, Phase 1/2 Clinical Trial in Sanfilippo Syndrome
type A (Mucopolysaccharidosis IIIA)Oral Presentation #039Presenter:
Maria Jose de Castro, M.D., Hospital Universitario Santiago de
CompostelaSession 4c: Metabolic and Genetic DiseasesDate/Time:
Friday, October 25, 2019, 9:00 a.m. to 11:00 a.m. CESTLocation:
Room 112
Novel AAV Capsids Show Increased Evasion to
Neutralizing Antibodies Against Natural SerotypesPoster
#P347Session Title: Poster Session IDate/Time: Wednesday, October
23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation: Multipurpose
Hall
Development of an Improved Novel AAV Capsids for Intramuscular
DeliveryPoster #P027Session Title: Poster Session IDate/Time:
Wednesday, October 23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation:
Multipurpose Hall
Novel AAV Capsids for Delivery to the Retina by Intravitreal
AdministrationPoster #P009Session Title: Poster Session IDate/Time:
Wednesday, October 23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation:
Multipurpose Hall
Development of a Novel AAV Capsid with Improved PNS Tropism for
Treating Pompe Disease by Intravenous AdministrationPoster
#P007Session Title: Poster Session IDate/Time: Wednesday, October
23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation: Multipurpose
Hall
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing gene and cell therapies for serious diseases.
The Company’s clinical programs include EB-101, its autologous,
gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene
therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS
IIIB), respectively. The Company’s portfolio of AAV9-based gene
therapies also features ABO-202 and ABO-201 for CLN1 disease and
CLN3 disease, respectively. Its preclinical assets include ABO-401,
which uses the novel AIM™ AAV vector platform to address all
mutations of cystic fibrosis. Abeona has received twenty regulatory
designations from the FDA and EMA for its pipeline candidates. For
more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements This press release
contains certain statements that are forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
and that involve risks and uncertainties. These statements
include statements about the Company’s clinical trials and its
products and product candidates, future regulatory interactions
with regulatory authorities, as well as the Company’s goals and
objectives. We have attempted to identify forward looking
statements by such terminology as “may,” “will,” “believe,”
“estimate,” “expect,” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances), which constitute and are intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, numerous risks and uncertainties,
including but not limited to continued interest in our rare disease
portfolio, our ability to enroll patients in clinical trials, the
outcome of any future meetings with the U.S. Food and Drug
Administration or other regulatory agencies, the impact of
competition, the ability to secure licenses for any technology that
may be necessary to commercialize our products, the ability to
achieve or obtain necessary regulatory approvals, the impact of
changes in the financial markets and global economic conditions,
risks associated with data analysis and reporting, and other risks
as may be detailed from time to time in the Company’s Annual
Reports on Form 10-K and quarterly reports on Form 10-Q and other
periodic reports filed by the Company with the Securities and
Exchange Commission. The Company undertakes no obligation to
revise the forward-looking statements or to update them to reflect
events or circumstances occurring after the date of this
presentation, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Investor Contact:Sofia Warner Senior Director,
Investor Relations Abeona Therapeutics +1 (646) 813-4710
swarner@abeonatherapeutics.com
Media Contact:Scott Santiamo Director,
Corporate Communications Abeona Therapeutics +1 (718) 344-5843
ssantiamo@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024